Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1512-1518

  Tan, Jiufeng ^a   Jin, Xuefei ^a   Zhao, Rui ^a   Wei, Xin ^a   Liu, Yan ^b   Kong, Xiangbo ^a  

^a JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

B lymphocytes; Inflammatory factors; Prostate cancer; T follicular helper cells

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PROSTAGLANDIN E2; IL10 PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; MESSENGER RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL INTERACTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE REARRANGEMENT; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T FOLLICULAR HELPER CELL; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; BLOOD; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROSTATE TUMOR;

ADULT; AGED; B-LYMPHOCYTES; CELLS, CULTURED; DINOPROSTONE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, MESSENGER; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84921683842     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3684     Document Type: Article

References (38)

1. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002.
2. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25:276-308, 2004.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269, 2007.
4. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454:436-444, 2008.
5. Sfanos KS and De Marzo AM: Prostate cancer and inflammation: the evidence. Histopathology 60:199-215. 2012
6. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP and Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep 32:1-15, 2012.
7. Salman H, Ori Y, Bergman M, Djaldetti M and Bessler H: Human prostate cancer cells induce inflammatory cytokine secretion by peripheral blood mononuclear cells. Biomed Pharmacother 66:330-333, 2012.
8. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357:539-545, 2001.
9. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V and Di Silverio F: Prostate growth and inflammation. J Steroid Biochem Mol Biol 108:254-260, 2008.
10. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell 140:883-899, 2010.
11. Sha W, Olesch C, Hanaka H, Rådmark O, Weigert A and Brüne B: Necrosis in Du145 prostate cancer spheroids induces CoX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation. Int j Cancer 133:1578-1588, 2013.
12. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP and Li Mo: T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35:123-134, 2011.
13. Jefferis R: Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 526:159-166, 2012.
14. Papadea C and Check IJ: Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic and clinical aspects. Crit Rev Clin Lab Sci 27:27-58, 1989.
15. Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, Ren XS, Sato H and Nakanuma Y: Significance of (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue. Hepatology 56:157-164, 2012.
16. Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG and van Baren N: Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 72:3997-4007, 2012.
17. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 123:1457-1474, 2013.
18. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, Takhar P, et al Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS one 6:e19330, 2011.
19. Platts-Mills TA, Woodfolk JA, Erwin EA and Aalberse R: Mechanisms of tolerance to inhalant allergens: the relevance of a modified Th2 response to aller gens from domestic animals. Springer Semin Immunopathol 25:271-279, 2004.
20. Satoguina JS, Weyand E, Larbi J and Hoerauf A: T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 174:4718-4726, 2005.
21. Crotty S: Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621-663, 2011.
22. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M and Förster R: Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles and support immunoglobulin production. J Exp Med 192:1545-1552, 2000.
23. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N and McHeyzer-Williams MG: Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 21:266-273, 2009
24. Davidson A and Aranow C: Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 6:13-20, 2010.
25. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, et al. Human blood CXCR5 (+) CD4 (+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34:108-121, 2011.
26. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R and Lanzavecchia A: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871-875, 2004
27. Neild GH, Rodriguez-Justo M, Wall C and Connolly JO: Hyper-IgG4 disease: report and characterization of a new disease. BMC Med 4:23, 2006.
28. Stone JH, Zen Y and Deshpande V: IgG4-related disease. N Engl J Med 366:539-551, 2012.
29. + T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci USA 108:E488-E497, 2011.
30. Aalberse RC and Schuurman J: IgG4 breaking the rules. Immunology 105:9-19, 2002.
31. Aalberse RC, Stapel So, Schuurman J and Rispens T: Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39:469-477, 2009.
32. French M: Serum IgG subclasses in normal adults. Monogr Allergy 19:100-107, 1986.
33. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M and Coussens LM: FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121-134, 2010.
34. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184:4006-4016, 2010.
35. Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET and Zou W: Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1:152-161, 2012.
36. English K, Tonlorenzi R, Cossu G and Wood KJ: Mesoangioblasts suppress T Cell proliferation through IDo and PGE-2-dependent pathways. Stem Cells Dev 22:512-523, 2013.
37. Chen YL, Chang MC, Chen CA, Lin HW, Cheng WF and Chien CL: Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS one 7:e47190, 2012.
38. Miyara M and Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13:108-116, 2007.